PhRMA sees strong FDA centers

Bush Administration FDA commissioner choice will not alter the "strong leadership role" played by the FDA centers, Pharmaceutical Research & Manufacturers of America Senior VP-Scientific & Regulatory Affairs Bert Spilker, MD/PhD, predicts at April 2 DIA meeting in Washington, D.C. "Most FDA commissioners previously have allowed the center directors to maintain their relative degree of independence...While the new FDA commissioner might in his or her view try to influence that, we see that major activities will still remain at the center"